Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

ELUT vs DBVT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ELUT
Elutia Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$45M
5Y Perf.-90.8%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+38.0%

ELUT vs DBVT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ELUT logoELUT
DBVT logoDBVT
IndustryBiotechnologyBiotechnology
Market Cap$45M$1712.35T
Revenue (TTM)$12M$0.00
Net Income (TTM)$53M$-168M
Gross Margin53.7%
Operating Margin-149.8%
Forward P/E0.8x
Total Debt$8M$22M
Cash & Equiv.$36M$194M

ELUT vs DBVTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ELUT
DBVT
StockOct 20May 26Return
Elutia Inc. (ELUT)1009.2-90.8%
DBV Technologies S.… (DBVT)100138.0+38.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: ELUT vs DBVT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ELUT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ELUT
Elutia Inc.
The Growth Play

ELUT carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth -49.6%, EPS growth 169.4%, 3Y rev CAGR -19.8%
  • -49.6% revenue growth vs DBVT's -100.0%
  • 434.2% margin vs DBVT's 0.3%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Long-Run Compounder

DBVT is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • -87.0% 10Y total return vs ELUT's -93.1%
  • Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
  • Beta 1.26, current ratio 3.67x
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthELUT logoELUT-49.6% revenue growth vs DBVT's -100.0%
Quality / MarginsELUT logoELUT434.2% margin vs DBVT's 0.3%
Stability / SafetyDBVT logoDBVTLower D/E ratio (12.8% vs 27.4%)
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs ELUT's -48.0%
Efficiency (ROA)ELUT logoELUT129.5% ROA vs DBVT's -89.0%

ELUT vs DBVT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ELUTElutia Inc.
FY 2024
Women's Health
79.9%$12M
Cardiovascular
20.1%$3M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ELUT vs DBVT — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLELUTLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ELUT leads this category, winning 1 of 1 comparable metric.

ELUT and DBVT operate at a comparable scale, with $12M and $0 in trailing revenue.

MetricELUT logoELUTElutia Inc.DBVT logoDBVTDBV Technologies …
RevenueTrailing 12 months$12M$0
EBITDAEarnings before interest/tax-$17M-$112M
Net IncomeAfter-tax profit$53M-$168M
Free Cash FlowCash after capex-$1M-$151M
Gross MarginGross profit ÷ Revenue+53.7%
Operating MarginEBIT ÷ Revenue-149.8%
Net MarginNet income ÷ Revenue+4.3%
FCF MarginFCF ÷ Revenue-11.5%
Rev. Growth (YoY)Latest quarter vs prior year-160.8%
EPS Growth (YoY)Latest quarter vs prior year+6.7%+91.5%
ELUT leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

DBVT leads this category, winning 2 of 2 comparable metrics.
MetricELUT logoELUTElutia Inc.DBVT logoDBVTDBV Technologies …
Market CapShares × price$45M$1712.35T
Enterprise ValueMkt cap + debt − cash$17M$1712.35T
Trailing P/EPrice ÷ TTM EPS0.77x-0.76x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue3.70x
Price / BookPrice ÷ Book value/share1.66x0.66x
Price / FCFMarket cap ÷ FCF
DBVT leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

ELUT leads this category, winning 5 of 7 comparable metrics.

ELUT delivers a 192.9% return on equity — every $100 of shareholder capital generates $193 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to ELUT's 0.27x. On the Piotroski fundamental quality scale (0–9), ELUT scores 5/9 vs DBVT's 4/9, reflecting solid financial health.

MetricELUT logoELUTElutia Inc.DBVT logoDBVTDBV Technologies …
ROE (TTM)Return on equity+192.9%-130.2%
ROA (TTM)Return on assets+129.5%-89.0%
ROICReturn on invested capital
ROCEReturn on capital employed-103.6%-145.7%
Piotroski ScoreFundamental quality 0–954
Debt / EquityFinancial leverage0.27x0.13x
Net DebtTotal debt minus cash-$29M-$172M
Cash & Equiv.Liquid assets$36M$194M
Total DebtShort + long-term debt$8M$22M
Interest CoverageEBIT ÷ Interest expense-189.82x
ELUT leads this category, winning 5 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $863 for ELUT. Over the past 12 months, DBVT leads with a +110.4% total return vs ELUT's -48.0%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ELUT's -24.1% — a key indicator of consistent wealth creation.

MetricELUT logoELUTElutia Inc.DBVT logoDBVTDBV Technologies …
YTD ReturnYear-to-date+55.3%+4.9%
1-Year ReturnPast 12 months-48.0%+110.4%
3-Year ReturnCumulative with dividends-56.2%+19.7%
5-Year ReturnCumulative with dividends-91.4%-69.1%
10-Year ReturnCumulative with dividends-93.1%-87.0%
CAGR (3Y)Annualised 3-year return-24.1%+6.2%
DBVT leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ELUT and DBVT each lead in 1 of 2 comparable metrics.

ELUT is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs ELUT's 37.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricELUT logoELUTElutia Inc.DBVT logoDBVTDBV Technologies …
Beta (5Y)Sensitivity to S&P 500-0.06x1.26x
52-Week HighHighest price in past year$2.64$26.18
52-Week LowLowest price in past year$0.50$7.53
% of 52W HighCurrent price vs 52-week peak+37.8%+76.3%
RSI (14)Momentum oscillator 0–10043.348.1
Avg Volume (50D)Average daily shares traded121K252K
Evenly matched — ELUT and DBVT each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricELUT logoELUTElutia Inc.DBVT logoDBVTDBV Technologies …
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$46.33
# AnalystsCovering analysts15
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ELUT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 2 (Valuation Metrics, Total Returns). 1 tied.

Best OverallElutia Inc. (ELUT)Leads 2 of 6 categories
Loading custom metrics...

ELUT vs DBVT: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is ELUT or DBVT a better buy right now?

Elutia Inc.

(ELUT) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ELUT or DBVT?

Over the past 5 years, DBV Technologies S.

A. (DBVT) delivered a total return of -69. 1%, compared to -91. 4% for Elutia Inc. (ELUT). Over 10 years, the gap is even starker: DBVT returned -87. 1% versus ELUT's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ELUT or DBVT?

By beta (market sensitivity over 5 years), Elutia Inc.

(ELUT) is the lower-risk stock at -0. 06β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately -2233% more volatile than ELUT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 27% for Elutia Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — ELUT or DBVT?

On earnings-per-share growth, the picture is similar: Elutia Inc.

grew EPS 169. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ELUT or DBVT?

Elutia Inc.

(ELUT) is the more profitable company, earning 434. 2% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 434. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -149. 8% for ELUT. At the gross margin level — before operating expenses — ELUT leads at 53. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — ELUT or DBVT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is ELUT or DBVT better for a retirement portfolio?

For long-horizon retirement investors, Elutia Inc.

(ELUT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 06)). Both have compounded well over 10 years (ELUT: -93. 0%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between ELUT and DBVT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELUT is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

ELUT

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 260%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.